Ilaprazole

Ilaprazole

Clinical data
Trade names	Noltec
Routes of administration	Oral
ATC code	None
Identifiers
IUPAC name 2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole
CAS Number	172152-36-2
PubChem CID	214351
ChemSpider	185839
UNII	776Q6XX45J
ChEMBL	CHEMBL2106370
Chemical and physical data
Formula	C19H18N4O2S
Molar mass	366.436820 g/mol
3D model (JSmol)	Interactive image
SMILES Cc1c(OC)ccnc1CS(=O)c2[nH]c3ccc(cc3n2)n4cccc4
InChI InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22) Key:HRRXCXABAPSOCP-UHFFFAOYSA-N

Ilaprazole (trade name Noltec) is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It is available in strengths of 5, 10, and 20 mg.

Clinical studies show that ilaprazole is at least as potent a PPI as omeprazole when taken in equivalent doses. Studies also showed that ilaprazole significantly prevented the development of reflux oesophagitis.

Ilaprazole is developed by Il-Yang Pharmaceutical (Korea), and is still under clinical trials with US FDA. It has launched in Korea and China for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux disease and erosive esophagitis.^[1]

References